Relación entre tabaco y sintomatología psicótica en paciente tratado con olanzapina oral. A propósito de un caso

Leal-Micharet, Antonio; Vaz-Leal, Francisco J; Méndez-Salguero, María J; Méndez-Sánchez, Fabiola; Baltasar-Tello, Itzíar; Gómez-Tovar, Belén; Gajardo-Galán, Virginia.
Actas esp. psiquiatr ; 42(5): 263-266, sept.-oct. 2014. tab
Artículo en Español | IBECS (España) | ID: ibc-128694

Documentos relacionados

  1. Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis.
  2. Application Prospect of Integrative Omics in Forensic Identification of Methamphetamine-Associated Psychosis.
  3. First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
  4. [Differential diagnostic distinction between substance-induced and primary psychoses: : Recommendations for general psychiatric and forensic practice].
  5. Clinical Challenges in Patients with First Episode Psychosis and Cannabis Use: Mini-Review and a Case Study.
  6. New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report.
  7. Methamphetamine use and psychotic symptoms: findings from a New Zealand longitudinal birth cohort.
  8. Cannabinoid-Induced Psychosis: A Cross-Sectional Gender Study.
  9. Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.
  10. Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.